A 3-month-old boy presented with an intranasal polypoidal mass protruding out of the nostril which was present since birth and growing slowly. The mass was non-pulsatile and soft to firm in consistency. It did not increase in size on coughing, crying, or compression of the jugular vein. Magnetic resonance imaging and contrast-enhanced computed tomography (CT) revealed a lobulated well-circumscribed soft tissue mass in the left nasal cavity with no intracranial communication. Complete surgical excision of the mass was carried out via an intranasal endoscopic approach. Histopathological examination confirmed the diagnosis of intranasal glioma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/ijpm.ijpm_57_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy.
ACS Appl Mater Interfaces
January 2025
Nanomedicine and Nanotoxicology Group, Physics Institute of São Carlos, São Paulo University, Avenida Trabalhador São Carlense, 400, São Carlos, SP 13560-970, Brazil.
Article Synopsis
- Glioblastoma (GBM) is a tough brain cancer to treat, but researchers are exploring the nose-to-brain drug delivery method as a potential solution.
- Nanoengineering has led to the creation of a specialized nanostructure (NP-MB) that combines a polymer core with Temozolomide (TMZ) and glioma cell membranes, enhancing drug delivery.
- The study shows that NP-MB effectively releases TMZ, is more toxic to glioma cells than conventional methods, reduces tumor size, and successfully reaches the brain, indicating its potential for advancing GBM therapy in clinical settings.
A promise of nose to brain delivery of bevacizumab intranasal sol-gel formulation substantiated in rat C6 glioma model.
Naunyn Schmiedebergs Arch Pharmacol
October 2024
Department of Pharmacology, Bombay College of Pharmacy, Santacruz East, Mumbai, 400098, India.
Glioblastoma is one of the rapidly spreading cancers, with its potent malignancy often linked to pronounced angiogenesis within tumors. To mitigate this vascularization profile, bevacizumab (Avastin®), a monoclonal antibody, has been utilized for its antiangiogenic activity. However, its effectiveness is hindered by challenges in crossing the blood-brain barrier and the risk of off-target organ toxicity.
View Article and Find Full Text PDFExploring intranasal drug delivery via nanocarriers: A promising glioblastoma therapy.
Colloids Surf B Biointerfaces
January 2025
Nanobioscience Group, Agharkar Research Institute, Pune 411004, India. Electronic address:
Glioblastoma is one of the most recurring types of glioma, having the highest mortality rate among all other gliomas. Traditionally, the standard course of treatment for glioblastoma involved maximum surgical resection, followed by chemotherapy and radiation therapy. Nanocarriers have recently focused on enhancing the chemotherapeutic administration to the brain to satisfy unmet therapeutic requirements for treating brain-related disorders.
View Article and Find Full Text PDFGlioblastoma Multiforme: Sensitivity to Antimicrobial Peptides LL-37 and PG-1, and Their Combination with Chemotherapy for Predicting the Overall Survival of Patients.
Pharmaceutics
September 2024
World-Class Research Center "Center for Personalized Medicine", Federal State Budgetary Institution of Science "Institute of Experimental Medicine", 197376 Saint Petersburg, Russia.
Glioblastomas (GBMs) are the most malignant and intractable of all cancers, with an unfavorable clinical prognosis for affected patients. The objective was to analyze the sensitivity of GBM cells to the antimicrobial peptides (AMPs) cathelicidin (LL-37) and protegrin-1 (PG-1), both alone and in combination with chemotherapy, to predict overall survival (OS) in the patients. The study was conducted on 27 GBM patients treated in the neurosurgical department of the Almazov Medical Research Centre (Saint Petersburg, Russia) from 2021 to 2024.
View Article and Find Full Text PDFDelivery of extracellular vesicles loaded with immune checkpoint inhibitors for immunotherapeutic management of glioma.
Mater Today Bio
October 2024
School of Pharmacy, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City, 701, Taiwan.
Glioma is a common primary malignant brain tumor with low survival rate. Immunotherapy with immune checkpoints inhibitors (ICI) can be a choice for glioma management, and extracellular vesicles (EVs) are recognized as a potential drug delivery system for various disease management due to their enhanced barrier permeation ability and immunomodulatory effect. The aim of this study is to develop ICI-loaded EVs (ICI/EV) that have sufficient efficacy in managing glioma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!